A multicenter randomized trial evaluating adjunctive intra-arterial tenecteplase after successful thrombectomy for acute basilar artery occlusion was stopped early for futility and safety concerns. The early termination underscores the difficulty of improving outcomes beyond mechanical reperfusion in posterior circulation stroke. The study design tested whether adding tenecteplase could improve functional outcomes when thrombectomy achieved recanalization. According to the trial report, the results did not meet the threshold for continued enrollment and raised concerns significant enough to halt the program. For stroke treatment development, the finding narrows the evidence base for pharmacologic add-ons after successful thrombectomy and may shift investigator focus toward alternative post-procedure strategies or better-defined patient subgroups. The early-stop signal also affects how developers plan future trials for combination approaches in large-vessel occlusion settings.